Cancer types
  • Lung
Title of study
Detection of circulating biomarkers of immunogenic cell death after radiotherapy and chemotherapy: an exploratory study
Version Number
Approval Date 
5, 23 March 2017
Short Title
Study site
Principle Investigator
D. De Ruysscher
Investigator Maastro
D. De Ruysscher
Maastricht Radiation Oncology
Trial registry

In this exploratory study, we will investigate if markers (molecular and immunological) of ICD or anti-tumour immunity (exosomal or molecular) can be detected in the serum of patients after high-dose radiotherapy alone or concurrent cisplatin-doublet therapy and radiotherapy

Primary Endpoint 

The study will be considered successful if, in at least one treatment group, one in ten patients has a detectable ICD biomarker

Secondary Endpoints 

1. Changes of relative protein expression / lipid profile for plasma / plasma-derived exosomes, linked to ICD.
2. Changes of relative protein expression, linked to Th1 / Th2 subsets.
3. Changes of relative protein expression, linked to vascular damage